Publications by authors named "Manon Penco-Campillo"
Article Synopsis
- Increased age is a significant unfavorable factor for glioblastoma (GBM) prognosis, but the interplay between patient age, comorbidities, and medications on survival has not been thoroughly studied.
- The study analyzed electronic health records of 565 GBM patients to evaluate the impact of age and various health conditions on survival and established potential targets for future research.
- Key findings revealed that younger patients had poorer outcomes related to movement disabilities and mental health issues, while older patients showed worse prognosis linked to epilepsy; both age groups benefited from Temozolomide and older patients from ACE-inhibitor prescriptions.
Article Synopsis
- Glioblastoma (GBM) is a severe brain tumor commonly found in older adults, often leading to poorer survival rates for patients aged 65 and older.
- The research involved studying patient data and conducting experiments on mice to analyze the effects of age on tumor characteristics and treatment outcomes.
- Findings indicated that older patients have worse survival rates, but combining senolytics (drugs targeting aging cells) with immunotherapy could enhance treatment effectiveness in older GBM patients.
Medulloblastoma (MB) is the most prevalent brain tumor in children. Although the current cure rate stands at approximately 70%, the existing treatments that involve a combination of radio- and chemotherapy are highly detrimental to the patients' quality of life. These aggressive therapies often result in a significant reduction in the overall well-being of the patients.
View Article and Find Full Text PDFMedulloblastoma (MB) is the most common and aggressive paediatric brain tumour. Although the cure rate can be as high as 70%, current treatments (surgery, radio- and chemotherapy) excessively affect the patients' quality of life. Relapses cannot be controlled by conventional or targeted treatments and are usually fatal.
View Article and Find Full Text PDFA Correction to this paper has been published: https://doi.org/10.1038/s42003-020-01502-2.
View Article and Find Full Text PDFMedulloblastoma (MB), the most common brain pediatric tumor, is a pathology composed of four molecular subgroups. Despite a multimodal treatment, 30% of the patients eventually relapse, with the fatal appearance of metastases within 5 years. The major actors of metastatic dissemination are the lymphatic vessel growth factor, VEGFC, and its receptors/co-receptors.
View Article and Find Full Text PDFTwo series of compounds carrying 3-amino-1,2,4-triazole scaffold were synthesized and evaluated for their anticancer activity against a panel of cancer cell lines using XTT assay. The 1,2,4-triazole synthesis was revisited for the first series of pyridyl derivatives. The biological results revealed the efficiency of the 3-amino-1,2,4-triazole core that could not be replaced and a clear beneficial effect of a 3-bromophenylamino moiety in position 3 of the triazole for both series (compounds 2.
View Article and Find Full Text PDF